ProCE Banner Activity

Antimicrobial Resistance in HABP/VABP: Strategies to Improve Empiric Regimens in the ICU

Slideset Download
Learn approaches to identify patients with HABP/VABP at risk for extensively drug–resistant organisms based on local resistance patterns and patient-specific factors, along with strategies, such as rapid diagnostic testing, advanced antibiograms, and clinical prediction scores, to help reduce time to effective therapy.

Released: October 21, 2022

Expiration: October 20, 2023

No longer available for credit.
Begin Activity

Share

Faculty

Keith S. Kaye

Keith S. Kaye, MD, MPH

Chief
Division of Allergy, Immunology and Infectious Diseases
Professor of Medicine
Rutgers Robert Wood Johnson Medical School
New Brunswick, New Jersey

Andrew Shorr

Andrew Shorr, MD, MPH, MBA

Director, Pulmonary and Critical Care Medicine
Washington, DC

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Merck Sharp & Dohme, LLC

Faculty Disclosure

Primary Author

Keith S. Kaye, MD, MPH

Chief
Division of Allergy, Immunology and Infectious Diseases
Professor of Medicine
Rutgers Robert Wood Johnson Medical School
New Brunswick, New Jersey

Keith S. Kaye, MD, MPH: ?i>consultant/advisor/speaker: Actavis, Allecra, Bayer, Carb-X, Cipla, Clarametyx, ContraFect, Cubist, Entasis, GlaxoSmithKline, Integrated Operations, Melinta, Merck, MicuRx, Nabriva, NS Nanotech, Pratek, Qpex, Shionogi, Spero, Utility, Venatorx, Xellia.

Andrew Shorr, MD, MPH, MBA

Director, Pulmonary and Critical Care Medicine
Washington, DC

Andrew Shorr, MD, MPH, MBA: consultant/advisor/speaker: Merck, Pfizer, Shionogi.